Rani Therapeutics Announces Research Agreement with Chugai
Rani Therapeutics (NASDAQ: RANI) has announced a Research Agreement with Chugai Pharmaceutical to evaluate the feasibility of applying Rani's oral delivery technology to Chugai's antibodies. The agreement, signed on August 13, 2024, covers two molecules with undisclosed targets. Initial analysis shows the RaniPill® delivery system achieved comparable bioavailability to subcutaneous delivery for both studied molecules.
Rani has previously evaluated 19 diverse molecules preclinically and completed three Phase 1 clinical trials with the RaniPill® capsule. The collaboration aims to leverage Rani's expertise in developing oral antibodies, peptides, and large proteins with high bioavailability alongside Chugai's technology-driven drug discovery approach.
Rani Therapeutics (NASDAQ: RANI) ha annunciato un Accordo di Ricerca con Chugai Pharmaceutical per valutare la fattibilità di applicare la tecnologia di somministrazione orale di Rani agli anticorpi di Chugai. L'accordo, firmato il 13 agosto 2024, riguarda due molecole con target non divulgati. L'analisi iniziale mostra che il sistema di somministrazione RaniPill® ha raggiunto una biodisponibilità comparabile alla somministrazione sottocutanea per entrambe le molecole studiate.
Rani ha precedentemente valutato preclinicamente 19 molecole diverse e completato tre studi clinici di Fase 1 con la capsula RaniPill®. La collaborazione mira a sfruttare l'esperienza di Rani nello sviluppo di anticorpi orali, peptidi e grandi proteine ad alta biodisponibilità, insieme all'approccio di Chugai basato sulla scoperta di farmaci guidata dalla tecnologia.
Rani Therapeutics (NASDAQ: RANI) ha anunciado un Acuerdo de Investigación con Chugai Pharmaceutical para evaluar la viabilidad de aplicar la tecnología de administración oral de Rani a los anticuerpos de Chugai. El acuerdo, firmado el 13 de agosto de 2024, cubre dos moléculas con objetivos no revelados. El análisis inicial muestra que el sistema de administración RaniPill® logró una biodisponibilidad comparable a la administración subcutánea para ambas moléculas estudiadas.
Rani ha evaluado previamente 19 moléculas diversas en estudios preclínicos y ha completado tres ensayos clínicos de Fase 1 con la cápsula RaniPill®. La colaboración tiene como objetivo aprovechar la experiencia de Rani en el desarrollo de anticuerpos orales, péptidos y proteínas grandes con alta biodisponibilidad, junto con el enfoque de Chugai basado en el descubrimiento de fármacos impulsado por tecnología.
Rani Therapeutics (NASDAQ: RANI)는 Chugai Pharmaceutical과 Rani의 경구 투여 기술을 Chugai의 항체에 적용할 수 있는 가능성을 평가하기 위한 연구 계약을 발표했습니다. 2024년 8월 13일에 체결된 이 계약은 비공개 타겟을 가진 두 분자를 포함합니다. 초기 분석 결과 RaniPill® 투여 시스템이 두 분자 모두에 대해 피하 투여와 유사한 생체이용률을 달성한 것으로 나타났습니다.
Rani는 이전에 19개의 다양한 분자를 비임상적으로 평가했으며 RaniPill® 캡슐로 3건의 1상 임상시험을 완료했습니다. 이번 협력은 고생체이용률을 가진 경구용 항체, 펩타이드 및 대형 단백질 개발에 대한 Rani의 전문성과 Chugai의 기술 중심 신약 개발 방식을 결합하는 것을 목표로 합니다.
Rani Therapeutics (NASDAQ : RANI) a annoncé un accord de recherche avec Chugai Pharmaceutical afin d'évaluer la faisabilité d'appliquer la technologie d'administration orale de Rani aux anticorps de Chugai. L'accord, signé le 13 août 2024, concerne deux molécules avec des cibles non divulguées. L'analyse initiale montre que le système d'administration RaniPill® a atteint une biodisponibilité comparable à celle de l'administration sous-cutanée pour les deux molécules étudiées.
Rani a déjà évalué précliniquement 19 molécules diverses et réalisé trois essais cliniques de phase 1 avec la capsule RaniPill®. Cette collaboration vise à tirer parti de l'expertise de Rani dans le développement d'anticorps oraux, peptides et grandes protéines à haute biodisponibilité, en complément de l'approche de découverte de médicaments axée sur la technologie de Chugai.
Rani Therapeutics (NASDAQ: RANI) hat eine Forschungsvereinbarung mit Chugai Pharmaceutical bekannt gegeben, um die Machbarkeit der Anwendung von Ranis oraler Verabreichungstechnologie auf Chugais Antikörper zu evaluieren. Die am 13. August 2024 unterzeichnete Vereinbarung umfasst zwei Moleküle mit nicht offengelegten Zielen. Erste Analysen zeigen, dass das RaniPill®-Verabreichungssystem für beide untersuchten Moleküle eine vergleichbare Bioverfügbarkeit wie die subkutane Verabreichung erreichte.
Rani hat zuvor 19 verschiedene Moleküle präklinisch bewertet und drei Phase-1-Studien mit der RaniPill®-Kapsel abgeschlossen. Die Zusammenarbeit zielt darauf ab, Ranis Expertise in der Entwicklung oraler Antikörper, Peptide und großer Proteine mit hoher Bioverfügbarkeit mit Chugais technologiegetriebener Wirkstoffforschung zu verbinden.
- Research agreement with major pharmaceutical company Chugai validates Rani's technology
- RaniPill® demonstrated comparable bioavailability to subcutaneous delivery
- Company has successfully evaluated 19 molecules preclinically and completed 3 Phase 1 trials
- None.
Insights
Rani Therapeutics' research agreement with Chugai validates their oral biologics delivery platform and expands partnership potential.
The research agreement between Rani Therapeutics and Chugai Pharmaceutical represents a significant validation of Rani's RaniPill® technology in the challenging space of oral biologics delivery. The data indicates their technology achieved comparable bioavailability to subcutaneous injection for both molecules studied - a remarkable technical achievement given the historical difficulties in oral delivery of large molecule drugs.
This collaboration with Chugai, a respected pharmaceutical company known for innovation, provides external validation from an established industry player. What makes this particularly noteworthy is the successful demonstration with antibodies, which are among the most challenging biologics to deliver orally due to their large molecular size and susceptibility to degradation in the gastrointestinal tract.
The press release highlights Rani's expanding track record, having now evaluated 19 diverse molecules preclinically and completed three Phase 1 clinical trials. This growing body of evidence supports the platform's versatility across different biological compounds.
While financial terms weren't disclosed, this type of feasibility assessment often precedes more substantial licensing or development agreements. This fits with Rani's business model of potentially partnering their delivery platform with pharmaceutical companies' proprietary molecules. For a clinical-stage company like Rani, these collaborative agreements can provide validation, potential milestone payments, and future royalty opportunities without the full development cost burden of bringing drugs to market independently.
- Research agreement is evaluating feasibility of applying Rani’s oral delivery technology to Chugai’s antibodies against undisclosed targets -
SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the company has entered into a Research Agreement on 13th August, 2024, for two molecules with undisclosed targets provided by Chugai Pharmaceutical Co., Ltd. ("Chugai"). The full analysis confirms the RaniPill® delivery demonstrated comparable bioavailability to the subcutaneous route of delivery for both molecules studied.
"We are delighted to explore the opportunity of a collaboration with Chugai, a world-class industry leader with deep research and development capabilities and a reputation for bringing innovation to patients,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “We believe Chugai's technology-driven drug discovery approach for innovation and development capabilities aligns seamlessly with Rani’s expertise in developing oral antibodies, peptides, and large proteins with high bioavailability. At Rani, to date, we have evaluated 19 diverse molecules preclinically and completed three Phase 1 clinical trials with the RaniPill® capsule, showcasing its broad applicability across a wide range of biologics.”
“At Chugai, we are committed to developing innovative drug discovery technologies based on our technology-driven approach. We are honored to have the opportunity to evaluate Rani’s technology, which proposes a pioneering and innovative approach that may potentially unlock significant value across multiple programs,” said Tom Igawa, PhD, Head of Research of Chugai Pharmaceutical Co., Ltd.
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit ranitherapeutics.com.
About Chugai Pharmaceutical
Chugai Pharmaceutical Co., Ltd., headquartered in Tokyo, is a research-based pharmaceutical company with world-class drug discovery capabilities, including proprietary antibody engineering technologies. Chugai is committed to creating innovative pharmaceutical products that may satisfy unmet medical needs. Chugai is listed on the Prime Market of the Tokyo Stock Exchange. While maintaining autonomy and management independence, Chugai is an important member of the Roche Group. Additional information is available at https://www.chugai-pharm.co.jp/english/.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the alignment of Rani’s and Chugai’s approach, capabilities and expertise, the broad applicability of the RaniPill® capsule technology, and the potential for the Rani technology to unlock value across multiple programs. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believe,” “potential,” “expect,” “may,” “could” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Rani’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Rani’s business in general and the other risks described in Rani’s filings with the Securities and Exchange Commission, including Rani’s annual report on Form 10-K for the year ended December 31, 2023, and subsequent filings and reports by Rani. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Rani undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investor Contact:
investors@ranitherapeutics.com
Media Contact:
FAQ
What is the purpose of the research agreement between Rani Therapeutics (RANI) and Chugai?
How many molecules has Rani Therapeutics (RANI) evaluated with its RaniPill technology?
What were the results of RaniPill's delivery system in the Chugai agreement?
When was the research agreement between Rani Therapeutics and Chugai signed?
